Upadacitinib
Indication
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA768)
MHRA Drug Safety Update, 26 April 2023
Brand:
Nice TA:
768
Commissioning responsibility:
CCG
PbR excluded:
Yes
Background
1.1 Upadacitinib, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to disease-modifying antirheumatic drugs (DMARDs) or who cannot tolerate them. It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and:
-
they have had 2 conventional DMARDs and at least 1 biological DMARD or
-
TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Upadacitinib is recommended only if the company provides it according to the commercial arrangement.